Followers | 80 |
Posts | 3,532 |
Boards Moderated | 0 |
Alias Born | 06/04/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
overhang on which entity 1:5 R/s Already announced on the other one
whats the conversion ratio if you had to guess ? 1:1 1:3 ?? 1:5
how can there be a forward split - doesnt make sense
a conversion from 1 to another would make more sense
then a UPLIST to major exchange would be my guess
do u own both EL and BF [already announced 1:5 R/S ]
YUP 'AGREE !!! Heard there will be $100s of Millions in Treasury from BOND SALE which was prev announced from the Tailings coming in - if not already in
like $300 million+ in the bank !!
https://elementglobal.com/subsidiaries/finance.php
and
major [some have already posted some clues] developments in Media / Streaming Media - that is the rumor
cant wait till the train starts
References
Clarinova will act as the finance, treasury and private equity arm for all of Element Global’s operations, divisions and subsidiaries. Clarinova Limited owns historic mining tailings that are currently valued at over 4 Billion USD. Clarinova has issued a zero coupon bond in the market place for 600 million euros and is currently being sold into the Euro marketplace.
Learn more at www.clarinova.eu
https://www.clarinova.eu/investments
https://www.clarinova.eu/images/files/extract-from-dekra-valuatio.pdf
https://finance.yahoo.com/news/element-global-inc-elgl-acquires-151500279.html
YUP !!!
PRED LinkedIn Employees TICK UP again on BioTech Division
appears they are gearing up something - hopefully sales !!
https://www.linkedin.com/company/predictive-biotech-inc/
https://www.linkedin.com/company/predictive-technology-group-inc/
https://www.linkedin.com/company/predictive-laboratories-inc/
what is this ??
I think it may be a Merry Xmas
yup Linked In numbers have been slowly increasing for weeks
$PRED Linked In Employees Numbers continue to tick UP
BioTech had 60 a few weeks back now 64
https://www.linkedin.com/company/predictive-biotech-inc/
https://www.linkedin.com/company/predictive-laboratories-inc/
https://www.linkedin.com/company/predictive-technology-group-inc/
Bravo Guru...!!
Tax Loss Selling
no not at all
taking shares back out from the broker and placed to the Transfer agent in Book Entry form
The shares cannot be sold or borrowed against in this form
the owner of the shares still owns the shares but has decided to remove them from the tradeable float
bodes confidence in the owner no need to sell in the foreseeable future
https://www.investopedia.com/terms/b/bookentrysecurities.asp
What Are Book-Entry Securities?
Book-entry securities are investments such as stocks and bonds whose ownership is recorded electronically. Book-entry securities eliminate the need to issue paper certificates of ownership. Ownership of securities is never physically transferred when they are bought or sold; accounting entries are merely changed in the books of the commercial financial institutions where investors maintain accounts.
Book-entry securities can also be referred to as uncertificated securities or paperless securities.
How Book-Entry Securities Work
Book entry is a method of tracking ownership of securities where no physically engraved certificate is given to investors. Securities are tracked electronically, rather than in paper form, allowing investors to trade or transfer securities without having to present a paper certificate as proof of ownership. When an investor purchases a security, they receive a receipt and the information is stored electronically.
Book-entry securities are settled by the Depository Trust Company (DTC), which is the Depository Trust & Clearing Corporation’s (DTCC) central securities depository. An investor receives a statement providing evidence of ownership instead of a stock certificate. Dividend payments, interest payments, and cash or stock payments due to a reorganization are processed by DTC and transferred to the appropriate investment bank or broker to deposit in the account of the securities’ holder. DTC sometimes may place temporary or permanent restrictions on certain transactions, such as deposits or withdrawals of certificates. Such a restriction is known as a chill. For example, DTC may impose a temporary chill that restricts the book-entry movement of securities, effectively closing the books and stabilizing existing positions until a merger or other reorganization has been completed.
All Happening this wk
Good news indeed thanks for sharing Shares starting to come out of the system
HELD At DTC Less by 1.5m so far
that means someone took shares with a broker and parked them BACK at the Transfer Agent in Book Entry Form
https://www.otcmarkets.com/stock/PRED/security
Lets hope this trend continues
$30/40 million in Revs
Top tier managemnt
Top Partners
Longs could go on and on too
PRED Shares Are Valuable. To support valuation, in part, consider:
Dr. Taylor's published research papers and data to be presented at ASRM, and the launch of PRED's ARTguide genetic diagnostics for endometriosis and the 24 million U.S. women who are symptomatic (and 14 million diagnosed) with endometriosis;
PRED's Mike Day who was the key executive that built Wyeth Women's Health, e.g., Wyeth was sold to Pfizer in 2009 for $68 billion;
John Sorrentino, PRED's Chairman who was until early this year COO and SVP at Pfizer responsible for $34+ billion in annual revenue;
And other seasoned individuals within PRED of equal track records in life science and public companies.
2019 ASRM and PRED's ARTguide:
ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Assisted Reproductive Technologies (ART), such as in-vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
Three scientific presentations by PRED's Dr. Hugh Taylor highlighting recent discoveries by Predictive Laboratories were selected through ASRM’s scientific peer-review process. The presentations will focus on several features of endometriosis, including genetic mechanisms (ARTguide) underlying the disorder, potential disease gene interactions, and the mechanisms through which some benign endometriosis lesions might become cancerous. The content of these presentations is embargoed until data are presented at the conference. Patent applications have been filed around these new discoveries adding to the Company’s robust endometriosis patent portfolio.
https://asrm.confex.com/asrm/2019/meetingapp.cgi/Person/739
The ARTguide Market and Revenue:
The market revenue from ARTguide is rather simple (remember there are 24 million endometriosis symptomatic undiagnosed women in the U.S.;
Survey data indicates all fertility clinics are interested in ARTguide;
A significant percentage (35 to 40%) of those clinics will order the ARTguide test for new patients;
And new and existing female patients equal an average of 35 prescriptions per month per doctor.
Initially, 15 larger clinics for clinical research are interested, and;
Assume 12 (of the 15 clinics), each with 9 doctors will produce $150 million in annual revenue from the ARTguide diagnostic;
Now consider 200 infertility doctors in the U.S. prescribing 35 prescriptions per month, which produces over $3.3 billion in annual revenue.
There are 480+ female reproduction and fertility doctors identified (highly confident) that will use ARTguide in the U.S.
The Big Picture Challange of Connecting the BIG FLASHING DOTS:
The 2019 American Society for Reproductive Medicine (ASRM) will be attended by 9,300 reproductive doctors, specialists, and scientists, from 94 countries, representing a diagnosed endometriosis population of 176 million, and an estimated undiagnosed population of another 128 million women (for those that have been paying attention, China has 74+ million women diagnosed with endometriosis).
https://asrmcongress.org/
Consider PRED's U.S. and internationally patented ARTguide diagnostic is being launched on the market at the world's leading reproductive conference (ASRM) attended by over 9,300 reproductive specialists, representing a global diagnosed and undiagnosed endometriosis population of 300+ million women.
https://www.rightdiagnosis.com/e/endometriosis/stats-country.htm
PRED's Near Term Market Cap?
Use the below PE, and note there are many other companion proprietary gene diagnostics and therapeutics in PRED's pipeline but let's just consider the multiples for ARTguide.
more clues ...INDIA thx
I wonder how Indian and Middle Eastern cuisine will digest when accompanied by PRED's ingredients? Perhaps CLSA has operations in other world regions?
Typically markets look out 6 or 12 months
not necessarily six weeks
but who says there won’t be new developments or even explosive news coming soon
I.e. China
Someone has been accumulating all these shares which have been in the 10s of Million s
Nothing Like a few hundred China Clinics to fire up the engines and perhaps a sweet cash infusion by CITIC
Stem Cells is NOT our future
Gene Based Therapies are
genetic and molecular diagnostics and companion therapeutics
Predictive Technology Group Reports First Quarter Fiscal 2020 Financial Results and Provides Corporate Update
Link...
https://finance.yahoo.com/news/predictive-technology-group-reports-first-211126298.html
SALT LAKE CITY (November 14, 2019) Predictive Technology Group, Inc. (OTCMARKETS: PRED) (“Predictive” or “The Company”), a leader in the development of genetic and molecular diagnostics and companion therapeutics, today announced financial results for the fiscal first quarter ended September 30, 2019 and provided a corporate update.
Management Commentary
“During our first fiscal quarter, we were able to sustain the momentum that carried us through fiscal 2019,” said Bradley C. Robinson, chief executive officer of Predictive Technology Group. “Total revenues for the quarter increased 2.5% year-over-year to $8.3 million, despite the difficult comparison driven by strong sales of human cell and tissue products (HCT/Ps) in the year-ago period.
“Since our last quarterly update, we successfully launched three new DNA-based test panels, including the full market launch of ARTguide™ following the successful Key Opinion Leader (KOL) beta launch, the KOL launch of FertilityDX™ and expanded distribution of PGxPLUS+™. ARTguide™, which helps detect genomic concerns associated with endometriosis and other infertility issues in women, has now been fully commercially launched and we expect material revenues to be generated beginning in calendar 2020. FertilityDX™, which is a comprehensive service that identifies infertility causes, optimizes infertility treatments and reduces risk of complications, is currently in a beta KOL development period. We are on track with the development and distribution of these fertility diagnostic tests that address an unmet need in the complex area of fertility and women’s health.
“In parallel, we achieved a significant milestone in our Predictive Biotech business, having now delivered over 100,000 allografts resulting in over 60,000 patient experiences with no serious adverse events attributable to our products, including AmnioCyte™, AmnioCyte Plus™, PolyCyte™ and CoreCyte™. Moving forward, in our Predictive Therapeutics business, we intend to pursue the FDA’s 351 regulatory pathway as we advance new cellular therapeutic candidates into clinical trials.
Securing FDA approval via this pathway requires a rigorous demonstration of a product’s efficacy and safety at a time when the agency has increased its focus on companies offering potentially unsafe human cell and tissue-based products as therapeutic agents. We are in a unique position with our HCT/P platform as the significant safety experience of over 100,000 allografts used in patients in the U.S. market provides the ability to accelerate and de-risk the clinical trial pathway for FDA approved indications. We will announce the specific indications for which we are pursuing FDA approval.
“We are in the early stages of unlocking significant synergies among our business subsidiaries and are working to further advance our broad pipeline of data analytics, therapeutics and diagnostics to benefit both patients and our stakeholders. We are fortunate to have highly experienced members of our advisory teams, management teams and board of directors to bring these products to market and truly improve the quality of life of individuals.”
Fiscal First Quarter and Recent Highlights
Predictive Laboratories
• Announced in October the successful U.S. launch of ARTguide™, the Company’s first integrated, DNA-based test to evaluate the risk for endometriosis and other genetic causes of infertility in women, and FertilityDX™, a comprehensive genetic testing service that identifies barriers to healthy pregnancy and birth, allowing doctors to guide personalized fertility treatments
• Presented new genetic findings in endometriosis at the 75th American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo
o The new findings were presented by Predictive Laboratories’ scientific team. Predictive Technology Group is a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention
o The presentations focused on several features of endometriosis, including genetic mechanisms underlying the disorder, potential disease gene interactions, and the mechanisms through which some benign endometriosis lesions might become cancerous
o Patent applications have been filed around these new discoveries adding to the Company’s robust endometriosis patent portfolio
• Announced that Predictive Laboratories has collected over 2,500 DNA samples along with comprehensive medical records since acquiring its CLIA operations in March 2019. The subsidiary is broadening its research initiatives by acquiring new sample collections in chronic pain, pregnancy complications, autism, and both female and male infertility to support the development of personalized molecular diagnostics and therapies
• In August, commercially launched PGxPLUS+™, a pharmacogenomic test panel being marketed to pain clinics for patients living with chronic pain
o PGxPLUS+™ evaluates genetic factors that play a major role in an individual’s response to medications
o Predictive Laboratories reached a milestone by enrolling 350 patients with chronic pain into an Investigational Review Board-approved clinical study aimed at providing additional insight into the mechanisms of chronic pain and responses to pain therapies
Predictive Biotech
• Delivered over 100,000 allografts resulting in over 60,000 patient experiences with no adverse events from AmnioCyte™, AmnioCyte Plus™, PolyCyte™ and CoreCyte™ products
Corporate Developments
• Announced that Kenneth Ward, M.D., laboratory director and chief executive officer of Juneau Biosciences, Rakesh Chettier M.S., director of biostatistics and Hans Albertsen, Ph.D., chief scientific officer of Juneau Biosciences, received the 2019 Endometriosis Special Interest Group (EndoSIG) Prize Paper in the “Best in Clinical/Population Science” category
• Appointed biologic industry leader Jeff Acuff to the newly created position of chief commercial officer of Predictive Biotech to drive the commercial strategy of its existing HCT/P business, including the development of new product candidates, and the expansion and use of the HCT/P into new vertical markets
• Appointed E. Robert Wassman, M.D. as co-laboratory director of Predictive Laboratories
• Engaged CLSA Capital Markets Limited to provide introductions to potential strategic partners and regulatory guidance to support the launch of Predictive’s proprietary genetic-based products into China’s rapidly growing women’s health and fertility markets
• Engaged LifeSci Partners as communications partner to develop and implement comprehensive investor relations and public relations programs
Fiscal First Quarter 2020 Results
Revenue from operations (net) for the three months ended September 30, 2019 totaled $8.3 million, compared with $8.1 million for the three months ended September 30, 2018. The increase of $0.2 million was the result of an expansion of the company’s sales force and distribution networks leading to increased sales of HCT/Ps and regenerative medicine products.
Cost of goods sold (“COGS”) includes expenses associated with acquisition and processing, manufacturing (including materials and direct labor), shipping, and other direct expenses relating to the company’s HCT/Ps and regenerative medicine products. Cost of goods sold for the three months ended September 30, 2019 was $7.2 million compared with $3.0 million for the three months ended September 30, 2018.
The increase is primarily due to $1.8 million in scrap expense and $1.2 million in increased inventory reserves related to HCT/P product that did not pass quality control, or that is not expected to pass quality control. The increase in quality control failure rates above normal levels was primarily due to a component supplied by a specific vendor. The remaining increase is due to increased share-based compensation cost of $0.4 million, increased personnel costs of $0.5 million, and increased facility costs of $0.2 million.
Sales and marketing expenses for the three months ended September 30, 2019 were $3.2 million, compared with $2.4 million for the three months ended September 30, 2018. The increased sales and marketing expenses resulted from increasing the headcount in the company’s sales force.
Research and development (R&D) expenses for the three months ended September 30, 2019 were $1.8 million, compared with $0.6 million for the three months ended September 30, 2018. The increased research and development expenses resulted from increased focus on product development and additional proprietary research and development work relating to the company’s HCT/Ps and regenerative medicine products. Additionally, we have invested significant amounts in laboratory support in anticipation of the sale of diagnostic products.
General and Administrative (G&A) expenses for the three months ended September 30, 2019 were $6.4 million compared with $2.7 million for the three months ended September 30, 2018. The changes in general and administrative expenses resulted from increased management headcount and share based compensation expense in fiscal 2020.
Amortization and depreciation expense for the three months ended September 30, 2019 was $2.6 million, compared with $1.7 million for the three months ended September 30, 2018. The reason for the increase in amortization and depreciation expense relates primarily to the amortization of intangible assets acquired from acquisitions.
The net loss attributable to common shareholders for the three months ended September 30, 2019 was $7.9 million, or $0.03 per share, versus a net loss attributable to common shareholders for the three months ended September 30, 2018 of $2.0 million, or $0.01 per share.
About Predictive Laboratories, Inc.
Predictive Laboratories’ discoveries in molecular and genetic diagnostics focus on unmet needs in women’s health, infertility and other diseases. Predictive Laboratories offers earlier detection of disease through genetic assessment to guide personalized precision medicine. Leveraging its vast genetic database, Predictive Laboratories enables the discovery of genes and gene mutations that identify hard-to-diagnose and detect diseases and their prognosis.
The Company’s proprietary tests include ARTguideTM and FertilityDXTM. ARTguideTM is a blood test that assesses a woman’s endometriosis risk and other genetic causes of infertility in order to optimally navigate the path towards conception. FertilityDXTM is a comprehensive test and service, using the parental genetic assessment as the map to guide the journey to successful pregnancy and a healthy newborn. Predictive Laboratories’ tests are processed at the Company’s state-of-the-art CAP-accredited, CLIA-certified laboratory, equipping physicians with the robust diagnostic tools to provide personalized treatment for their patients. For more information, visit http://www.predictivelabs.com.
About Predictive Biotech, Inc.
Predictive Biotech, Inc., a Salt Lake City-based life sciences company formed in 2015, is a leader in human cell and tissue products for use in cellular therapies and regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage Predictive’s four main placental-derived and Wharton’s Jelly umbilical cord-derived products. Predictive Biotech’s current products are regulated by the FDA under 21 CFR part 1271 section 361 as minimally manipulated allografts intended for homologous use.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit http://www.predtechgroup.com.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
For more information, visit http://www.predtechgroup.com
100k Bidding from $1 on the close
tomorrow will be interesting
no one said R/Split
if shares with a Broker are requested to go back to the Transfer Agent in Book Entry Form - with just a few signed documents
presto ... the float reduces
if enough executives take the same actions the float would be reduced significantly and also make LESS Shares available to borrow against
Lord help the shorts when big news or buying comes back
or
perhaps insiders after the Q feel the share price is a bargain and actually put their money where their mouths' are and gobble up additional shares hence reducing the float even more
and
if they transfer those shares again with TA ....
Lets Squeeze any shorts here - time to reverse
Go PRED
OTC APPROVED PRED
Totally BS by OTC - Seems like OTC is Corrupt
Appears OTC Works with the Shorts as many have indicated
PRED ran to $7 on OTC so who cares
Lets focus on Nasdaq and beyond, the upcoming Quarterly Results reviews by Deliotte / potential updates from Management
China etc !!!
Many other positive things to focus on
FYI PRED LinkedIN Employee Count are Ticking Higher
BioTech
https://www.linkedin.com/company/predictive-biotech-inc/
Technology
https://www.linkedin.com/company/predictive-technology-group-inc/
Labratories
https://www.linkedin.com/company/predictive-laboratories-inc/
Good .. let’s get to Nasdaq already
he is manipulating info / fraudulently too
prob working with shorts seen 1000's of times on the msg board
Current mgnt have not and are not dumping - would be illegal especially during lock up / quiet periods - time close to Earnings and / or material events being negotiated - like CITIC / CLSA
management have buy in options North of $2
however former management that have no current relationship with the co may do as they wish -
Hindenburg mentioned former management in the same BS regard
was proven not true and former management is not present management
Current Execs didn't sell - would be illegal without disclosing
dont listen to those working w shorts
Current Executives have not sold or would have been disclosed
cannot account for former employees or former Executives that is their business
go PRED !!
PRED NEWS - Predictive Engages LifeSci Partners as Communucations Partner http://www.lifescipartners.com/
SALT LAKE CITY , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTCQX: PRED) (“Predictive” or “The Company”), a leader in the development of genetic and molecular diagnostics and companion therapeutics, announced that it has engaged with LifeSci Partners (“LifeSci”) to increase awareness of the company’s brand and clinical programs.
“We are excited to work with LifeSci to inform the public and the investment community about our innovative data analytics that help physicians identify and combat diseases using our unique treatments and therapeutics,” said Bradley C. Robinson , president and chief executive officer of Predictive. “LifeSci’s expertise in investor relations and public relations, as well as their decades of experience in capital markets, media relations and scientific research have made them the perfect communications partner for our company as we work to grow our business and reach new audiences.”
LifeSci is a leading provider of strategic consulting services in the areas of investor relations, public relations, corporate communications, executive search and capital markets advisory. LifeSci Advisors, LLC and LifeSci Public Relations will provide Predictive with integrated communications services through strategic messaging, investor and media outreach, social and digital media efforts.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories , Predictive Biotech and Predictive Therapeutics For more information, visit www.predtechgroup.com.
About LifeSci Advisors
LifeSci Advisors is a division of LifeSci Partners (http://www.lifescipartners.com), a leading provider of consulting services for life sciences clients in the areas of investor relations, public relations, corporate communications, executive search, strategic partnering and capital markets advisory.
LifeSci combines deep domain expertise and decades of experience in capital markets and communications with a global network to deliver unparalleled services to clients. LifeSci Advisors is the largest investor relations consultancy in the life sciences industry, founded to provide companies with a multi-faceted approach to investor communications and outreach.
LifeSci Advisor’s team of financial services and investor relations specialists synergistically pair with LifeSci Public Relations’ team of MDs and PhDs, positioning the firm to best communicate its clients’ scientific, R&D, regulatory and commercial strategies to diverse audiences.
LifeSci Partners’ addition of executive search, strategic partnering and capital markets advisory capabilities provides fully integrated business solutions for life sciences clients across all stages of development.
Forward-Looking Statements:
Contacts:
For more information, visit http://www.predtechgroup.com
or
contact:
Media Contact
Patrick Bursey
LifeSci Public Relations
http://lifescipublicrelations.com/
pbursey@lifescipublicrelations.com
646-876-4932
Investor Contact
Jeremy Feffer
LifeSci Advisors
https://www.lifesciadvisors.com/
jeremy@lifesciadvisors.com
212-915-2568
could this be a Comparable or Competitor to PRED .. PGNY
https://progyny.com/ Did about $100 million in REVS and $4 in Profits
https://finance.yahoo.com/news/fertility-progyny-climbs-debut-below-175818378.html